Therapeutic Effects of Reboxetine in the Adult Patients with Attention-Deficit/Comparing Therapeutic Effects of Reboxetine with Placebo in Adult Patients with Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled Clinical Trial
Author(s):
Abstract:
Background And Objective
Attention-deficit-hyperactivity disorder (ADHD) in adults is accompanied with different complications such as decreased occupational and educational performance. At present, stimulant drugs are used as the first line treatment in this disorder. However, possible development of side effects and dependence on these drugs are of concern. Therefore, it was decided to evaluate the efficacy of reboxetine in the treatment of adults with attention-deficit-hyperactivity disorder. Subjects and Methods
Forty adult diagnosed with ADHD without any significant psychiatric disorder were participated in a 6-weeks a double blind clinical trial with reboxetine (8 mg/d) in two divided doses. The principle measured outcome was the Conner's ADHD Rating Scale (adult version). Results
Rate of response (decrease of Conner’s rating scale scores) in reboxetine group were significantly greater than control group (pLanguage:
Persian
Published:
Jundishapur Scientific Medical Journal, Volume:9 Issue: 5, 2010
Page:
483
magiran.com/p793778
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یکساله به مبلغ 1,390,000ريال میتوانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.
In order to view content subscription is required
Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!